Cargando…

Knockdown of AKR1C3 Promoted Sorafenib Sensitivity Through Inhibiting the Phosphorylation of AKT in Hepatocellular Carcinoma

BACKGROUND: Sorafenib, which can induce ferroptosis, is a multikinase inhibitor for enhancing survival in advanced hepatocellular carcinoma (HCC). However, a considerable challenge for the treatment of HCC is sorafenib resistance. Therefore, targeting the relationship between sorafenib resistance an...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zheng, Jia, Yang, Zhihong, Li, Yanlei, Yang, Li, Yao, Ruili
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8963762/ https://www.ncbi.nlm.nih.gov/pubmed/35359392 http://dx.doi.org/10.3389/fonc.2022.823491

Ejemplares similares

SENP2 Reduces Hepatocellular Carcinoma Stemness and Improves Sorafenib Sensitivity Through Inactivating the AKT/GSK3β/CTNNB1 Pathway
por: Tang, Xiaohui, et al.
Publicado: (2021)

Oridonin Sensitizes Hepatocellular Carcinoma to the Anticancer Effect of Sorafenib by Targeting the Akt Pathway
por: Li, Xuguang, et al.
Publicado: (2020)

CISD2 Promotes Resistance to Sorafenib-Induced Ferroptosis by Regulating Autophagy in Hepatocellular Carcinoma
por: Li, Bowen, et al.
Publicado: (2021)

Development of an Aerobic Glycolysis Index for Predicting the Sorafenib Sensitivity and Prognosis of Hepatocellular Carcinoma
por: Pan, Yu, et al.
Publicado: (2021)

FNDC5 Causes Resistance to Sorafenib by Activating the PI3K/Akt/Nrf2 Pathway in Hepatocellular Carcinoma Cells
por: Liu, Huayuan, et al.
Publicado: (2022)

Camrelizumab Plus Sorafenib Versus Sorafenib Monotherapy for Advanced Hepatocellular Carcinoma: A Retrospective Analysis
por: Liu, Qinqin, et al.
Publicado: (2021)

Knockdown of NDUFC1 inhibits cell proliferation, migration, and invasion of hepatocellular carcinoma
por: Han, Fang, et al.
Publicado: (2022)

ATPase Inhibitory Factor 1 Promotes Hepatocellular Carcinoma Progression After Insufficient Radiofrequency Ablation, and Attenuates Cell Sensitivity to Sorafenib Therapy
por: Kong, Jian, et al.
Publicado: (2020)

AKR1B10 inhibits the proliferation and metastasis of hepatocellular carcinoma cells by regulating the PI3K/AKT pathway
por: Tian, Ke, et al.
Publicado: (2023)

The Role of Non-Coding RNAs in the Sorafenib Resistance of Hepatocellular Carcinoma
por: Hu, Xinyao, et al.
Publicado: (2021)

Knockdown of SNORA47 Inhibits the Tumorigenesis of NSCLC via Mediation of PI3K/Akt Signaling Pathway
por: Yu, Huiqing, et al.
Publicado: (2021)

Effect of the Hypoxia Inducible Factor on Sorafenib Resistance of Hepatocellular Carcinoma
por: Zeng, Zhi, et al.
Publicado: (2021)

GHR knockdown enhances the sensitivity of HCC cells to sorafenib
por: Gao, Shuang, et al.
Publicado: (2020)

Avasimibe Dampens Cholangiocarcinoma Progression by Inhibiting FoxM1-AKR1C1 Signaling
por: Gao, Yunshu, et al.
Publicado: (2021)

Prognostic Nomogram for Sorafenib Benefit in Hepatitis B Virus-Related Hepatocellular Carcinoma After Partial Hepatectomy
por: Dong, Wei, et al.
Publicado: (2021)

LETM1 Knockdown Promotes Autophagy and Apoptosis Through AMP-Activated Protein Kinase Phosphorylation-Mediated Beclin-1/Bcl-2 Complex Dissociation in Hepatocellular Carcinoma
por: Zhou, Baoyong, et al.
Publicado: (2021)

Efficacy and safety of lenvatinib versus sorafenib in first-line treatment of advanced hepatocellular carcinoma: A meta-analysis
por: Luo, Jia, et al.
Publicado: (2022)

siAKR1C3@PPA complex nucleic acid nanoparticles inhibit castration-resistant prostate cancer in vitro
por: Cui, Xiaoli, et al.
Publicado: (2022)

Knockdown of FBI-1 Inhibits the Warburg Effect and Enhances the Sensitivity of Hepatocellular Carcinoma Cells to Molecular Targeted Agents via miR-3692/HIF-1α
por: Liu, Juan, et al.
Publicado: (2021)

Nivolumab Versus Regorafenib in Patients With Hepatocellular Carcinoma After Sorafenib Failure
por: Kuo, Yuan-Hung, et al.
Publicado: (2021)

Hepatocellular Carcinoma With Portal Vein Tumor Thrombus Treated With Transarterial Chemoembolization and Sorafenib vs. (125)Iodine Implantation
por: Hu, Hong-Tao, et al.
Publicado: (2021)

Improving the Therapeutic Efficacy of Sorafenib for Hepatocellular Carcinoma by Repurposing Disulfiram
por: Zhang, Gong, et al.
Publicado: (2022)

Inhibition of Glyoxalase-I Leads to Reduced Proliferation, Migration and Colony Formation, and Enhanced Susceptibility to Sorafenib in Hepatocellular Carcinoma
por: Michel, Maurice, et al.
Publicado: (2019)

BEZ235 Increases the Sensitivity of Hepatocellular Carcinoma to Sorafenib by Inhibiting PI3K/AKT/mTOR and Inducing Autophagy
por: Cao, Weiya, et al.
Publicado: (2021)

Inhibition of neddylation modification by MLN4924 sensitizes hepatocellular carcinoma cells to sorafenib
por: Yang, Zelong, et al.
Publicado: (2019)

Oridonin Sensitizes Hepatocellular Carcinoma to the Anticancer Effect of Sorafenib by Targeting the Akt Pathway [Corrigendum]
Publicado: (2021)

Non-coding RNAs: Emerging Regulators of Sorafenib Resistance in Hepatocellular Carcinoma
por: Lai, Yongting, et al.
Publicado: (2019)

Survival and adverse events of elderly patients treated with sorafenib for hepatocellular carcinoma
por: Soria, Anna, et al.
Publicado: (2022)

Hepatic Arterial Infusion Chemotherapy of Oxaliplatin, Fluorouracil, and Leucovorin With or Without Sorafenib as Initial Treatment for Advanced Hepatocellular Carcinoma
por: Liang, Run-Bin, et al.
Publicado: (2021)

Prognostic Roles of Blood Inflammatory Markers in Hepatocellular Carcinoma Patients Taking Sorafenib. A Systematic Review and Meta-Analysis
por: Liu, Lixing, et al.
Publicado: (2020)

Deep Learning Predicts Overall Survival of Patients With Unresectable Hepatocellular Carcinoma Treated by Transarterial Chemoembolization Plus Sorafenib
por: Zhang, Lei, et al.
Publicado: (2020)

AKR1B10 Inhibitor Epalrestat Facilitates Sorafenib-Induced Apoptosis and Autophagy Via Targeting the mTOR Pathway in Hepatocellular Carcinoma
por: Geng, Nan, et al.
Publicado: (2020)

Knockdown of MUC16 (CA125) Enhances the Migration and Invasion of Hepatocellular Carcinoma Cells
por: Huang, Yao, et al.
Publicado: (2021)

Hsa-miR-4277 Decelerates the Metabolism or Clearance of Sorafenib in HCC Cells and Enhances the Sensitivity of HCC Cells to Sorafenib by Targeting cyp3a4
por: He, Xi, et al.
Publicado: (2021)

Diffuse Recurrence of Hepatocellular Carcinoma After Liver Resection: Transarterial Chemoembolization (TACE) Combined With Sorafenib Versus TACE Monotherapy
por: Yao, Wang, et al.
Publicado: (2020)

Sorafenib and CuB exert synergistic antitumor effects against hepatocellular carcinoma cells via inhibition of STAT3 phosphorylation
por: Wang, Xiaoli, et al.
Publicado: (2020)

Cancer-Associated Fibroblasts Promote the Upregulation of PD-L1 Expression Through Akt Phosphorylation in Colorectal Cancer
por: Gao, Yang, et al.
Publicado: (2021)

Prognostic Performance of Albumin–Bilirubin Grade With Artificial Intelligence for Hepatocellular Carcinoma Treated With Transarterial Chemoembolization Combined With Sorafenib
por: Zhong, Bin-Yan, et al.
Publicado: (2020)

Camptothecin improves sorafenib sensitivity by inhibiting Nrf2‑ARE pathway in hepatocellular carcinoma
por: Sun, Liwei, et al.
Publicado: (2023)

Corrigendum: Non-coding RNAs: Emerging Regulators of Sorafenib Resistance in Hepatocellular Carcinoma
por: Lai, Yongting, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_d5le1ggui3sa0vsohrubou3qal